Hematologic Oncology | Specialty

Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies

July 14th 2020

Kami J. Maddocks, MD, discusses the role of zanubrutinib in B-cell malignancies.

First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma

July 13th 2020

In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.

Carving Out New Combination Therapies in Stem Cell Disorders

July 13th 2020

Despite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement.

Dr. Verstovsek on the Rationale Behind Treating Myelofibrosis With CPI-0610/Ruxolitinib

July 13th 2020

Srdan Verstovsek, MD, PhD, discusses research efforts being made with CPI-0610 in the treatment of patients with myelofibrosis.

Dr. Tzachanis on the Likelihood of Cure With CAR T-Cell Therapy in Lymphoma

July 13th 2020

Dimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.

Experts Explore Treatment Approaches With Novel Agents in ALL

July 11th 2020

A panel of experts in acute lymphoblastic leukemia broach the topic of innovative approaches incorporating novel agents in clinical practice.

Panel of Experts Cover Clinical Scenarios in AML

July 11th 2020

A panel of experts in acute myeloid leukemia (AML) consider potential treatment options for patients with AML

Dr. Daver on Updated Findings With Magrolimab/Azacitidine in MDS

July 10th 2020

Naval G. Daver, MD, discusses updated findings on the combination of the investigational CD47-directed antibody magrolimab and azacitidine in myelodysplastic syndrome.

Oral Rigosertib Demonstrates Early Signs of Efficacy in MDS/AML

July 10th 2020

The investigational small molecule RAS mimetic rigosertib in combination with azacitidine elicited encouraging efficacy and a tolerable safety profile in patients with higher-risk myelodysplastic syndromes, acute myeloid leukemia, or chronic myelomonocytic leukemia.

NICE Recommends Frontline Brentuximab Vedotin Combo for Systemic Anaplastic Large Cell Lymphoma

July 9th 2020

The United Kingdom’s National Institute for Health and Care Excellence has recommended brentuximab vedotin (Adcetris) in combination with cyclophosphamide, doxorubicin, and prednisone as a treatment option in treatment-naïve patients with systemic anaplastic large cell lymphoma.

FDA Grants Priority Review to Second-Line Pembrolizumab in Relapsed/Refractory Hodgkin Lymphoma

July 9th 2020

The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab monotherapy as a treatment for adult patients with relapsed/refractory classical Hodgkin lymphoma.

Dr. Talati on Rationale for Collecting Real-World Data on Venetoclax/HMA Combos in AML

July 8th 2020

Chetasi Talati, MD, discusses the design of a chart review study with venetoclax and hypomethylating agents in older patients with newly-diagnosed acute myeloid leukemia.

Dr. Neelapu on Potential Advantages of Allogeneic CAR T-Cell Therapy in Lymphoma

July 7th 2020

Sattva Neelapu, MD, discusses the potential advantages of allogeneic CAR T-cell therapy compared with autologous CAR T-cell therapy in lymphoma.

Dr. Hoffman on Advantages of Self-Administration With PTG-300 in Polycythemia Vera

July 7th 2020

Ronald Hoffman, MD, discusses the advantages of self-administration with the investigational hepcidin mimetic PTG-300 for patients with polycythemia vera (PV).

Advances in the Management of MPNs

July 7th 2020

Essential Thrombocythemia: Treatment Optimization

July 7th 2020

Classifying Patients With Essential Thrombocythemia

July 7th 2020

Primary Myelofibrosis: Trials of Interest

July 7th 2020

JAK2 Inhibitor Selection for Primary Myelofibrosis

July 7th 2020

Fedratinib for Primary Myelofibrosis

July 7th 2020